Open Payments

Butler Hospital

Type
Teaching hospital
Where
Providence, RI
Medicare CCN
414000
Received
$1,850,404 in 81 records, 2025 ($0 general, $1,850,404 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025Research payment81$1,850,404

By company

CompanyRecordsAmountYears
Eisai Inc.48$972,2752025
Eli Lilly and Company6$441,2912025
Janssen Research & Development, LLC22$275,0902025
E.R. Squibb & Sons, L.L.C.2$112,5492025
Biogen, Inc.2$39,1972025
Neuronetics, Inc.1$10,0002025

By nature of payment

NatureRecordsAmount
Research payment81$1,850,404

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-29Janssen Research & Development, LLC$14,688Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-12-22Janssen Research & Development, LLC$23,086Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-12-22Janssen Research & Development, LLC$13,411Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-12-19Janssen Research & Development, LLC$16,706Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-12-15Eisai Inc.$9,880Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-12-01Eisai Inc.$37,870Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-12-01Eisai Inc.$7,600Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-12-01Eisai Inc.$7,180Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-11-17Eisai Inc.$11,943Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-11-03Janssen Research & Development, LLC$2,501Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-11-03Janssen Research & Development, LLC$871Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-11-01Eisai Inc.$42,340Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-11-01Eisai Inc.$6,620Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-11-01Eisai Inc.$3,800Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-10-21Eisai Inc.$288Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-10-20Eisai Inc.$14,737Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-10-01Eisai Inc.$62,035Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-10-01Eisai Inc.$43,145Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-10-01Eisai Inc.$16,400Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-10-01Eisai Inc.$15,200Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-10-01Eisai Inc.$11,400Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-09-15Eisai Inc.$18,716Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-09-15Eisai Inc.$975Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-09-05Janssen Research & Development, LLC$1,936Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-09-01Eisai Inc.$37,870Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-09-01Eisai Inc.$22,800Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-09-01Eisai Inc.$15,375Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-09-01Eisai Inc.$15,200Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-09-01Eisai Inc.$11,400Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-08-11Eisai Inc.$23,786Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-08-11Janssen Research & Development, LLC$17,684Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-08-04Janssen Research & Development, LLC$16,444Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-08-04Janssen Research & Development, LLC$4,270Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-07-21Eli Lilly and Company$36,703Research paymentCash or cash equivalentAMYVID Drug, NeuroscienceA STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC2025
2025-07-21Eisai Inc.$21,461Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-07-21Eisai Inc.$216Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-07-07Eisai Inc.$18,302Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-07-07Janssen Research & Development, LLC$3,343Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-07-01Eisai Inc.$63,770Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-07-01Eisai Inc.$33,515Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-07-01Eisai Inc.$13,580Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-07-01Eisai Inc.$7,600Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-07-01Eisai Inc.$5,160Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-07-01Eisai Inc.$1,690Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-06-24Eli Lilly and Company$131Research paymentIn-kind items and servicesLONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH 2025
2025-06-12Janssen Research & Development, LLC$11,407Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-06-01Eisai Inc.$41,040Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-06-01Eisai Inc.$8,565Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-06-01Eisai Inc.$7,600Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-06-01Eisai Inc.$911Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-06-01Eisai Inc.$911Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-05-16Eli Lilly and Company$72Research paymentIn-kind items and servicesKISUNLA Drug, NeuroscienceA STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6)2025
2025-05-12Janssen Research & Development, LLC$4,304Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-05-08Janssen Research & Development, LLC$8,245Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-04-23Eli Lilly and Company$2,194Research paymentIn-kind items and servicesA STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC2025
2025-04-14Janssen Research & Development, LLC$32,492Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-04-01Eisai Inc.$36,285Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-04-01Eisai Inc.$9,030Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-03-24Janssen Research & Development, LLC$228Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-03-20Eisai Inc.$113,663Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-03-17Eisai Inc.$582Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-03-07Janssen Research & Development, LLC$15,994Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-03-06Neuronetics, Inc.$10,000Research paymentCash or cash equivalentNEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEMIIT Study2025
2025-03-01Eisai Inc.$35,545Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-03-01Eisai Inc.$9,210Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-02-25E.R. Squibb & Sons, L.L.C.$4,348Research paymentCash or cash equivalentA Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-92025
2025-02-07Janssen Research & Development, LLC$38,375Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-02-05Eli Lilly and Company$363,895Research paymentCash or cash equivalentLONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH 2025
2025-02-03Janssen Research & Development, LLC$41,481Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62025
2025-02-03Janssen Research & Development, LLC$5,000Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-02-03Janssen Research & Development, LLC$1,824Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-02-03Janssen Research & Development, LLC$798Research paymentCash or cash equivalentA Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immuno2025
2025-02-01Eisai Inc.$13,855Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-02-01Eisai Inc.$6,000Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-01-21E.R. Squibb & Sons, L.L.C.$108,201Research paymentCash or cash equivalentA Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-92025
2025-01-21Eli Lilly and Company$38,295Research paymentCash or cash equivalentA STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6)2025
2025-01-21Eisai Inc.$26,423Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2025
2025-01-07Biogen, Inc.$36,932Research paymentCash or cash equivalentADUHELM Biological, NeurologyA Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene2025
2025-01-07Biogen, Inc.$2,265Research paymentCash or cash equivalentADUHELM Biological, NeurologyPhase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ2025
2025-01-01Eisai Inc.$53,055Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025
2025-01-01Eisai Inc.$7,740Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment 2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Providence CountyProvidence city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Providence, RI, county Providence County, RI, state Rhode Island; placed by its city name.

MeasurePlace (city or town)
Providence, RI
County
Providence County, RI
State
Rhode Island
Population B01003191,767664,8541,101,801
Population, 2020 census P1190,934660,7411,097,379
Median age B0100232.838.040.6
Under 18 B0100120.1%20.1%18.8%
65 and over B0100111.6%16.3%18.7%
Households B1100171,497259,210441,570
Foreign born B0500233.5%20.9%15.3%
Median household income B19013$68,119$78,787$87,796
Median family income B19113$80,994$99,120$112,375
Per capita income B19301$37,138$41,523$47,150
Poverty rate B1700120.7%13.4%11.2%
Unemployment rate B230258.2%6.6%5.8%
Civilian labor force B23025101,717358,122594,253
Mean commute (minutes) B0801325.025.925.5
Bachelor's degree or higher B1500334.6%32.3%37.7%
Housing units B2500179,423277,740485,932
Owner-occupied B2500341.4%56.9%63.6%
Renters B2500358.6%43.1%36.4%
Median home value B25077$362,200$373,600$404,200
Median gross rent B25064$1,408$1,312$1,342
White, not Hispanic B0300233.1%56.5%68.0%
Black B0300210.2%7.0%4.9%
Hispanic or Latino B0300245.3%25.6%17.7%
Asian B030026.2%4.2%3.5%
American Indian and Alaska Native B030020.3%0.2%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Providence, RI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.